TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06140654

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical oral examination
Description: Clinical oral examinations are conducted by a dental practitioner. They point out the number of teeth (ranging from 0 to 32), the number of occlusal functional units (OFU, ranging from 0 to 10, with one unit considered as a pair of antagonist premolars and molars that had at least one contact area during maximum intercuspal relationships, evaluated by asking the participants to clench on a 200 µm thick articulating paper, the presence of dental prostheses (fixed prosthesis and removable denture), the number of denture worn during meals (removable partial or complete denture, either maxillary or mandibular, or both, with number ranging from 0 to 2), the number of decayed, missing, filled teeth (DMFT index, based on 28 teeth), and the Russel's periodontal index which is presently preferred to the Community (namely CPITN) because it takes tooth mobility into account.
Study: NCT01612013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC plus sodium bicarbonate plus saline
Description: Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study: NCT06140654

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical oral examination
Description: Clinical oral examinations are conducted by a dental practitioner. They point out the number of teeth (ranging from 0 to 32), the number of occlusal functional units (OFU, ranging from 0 to 10, with one unit considered as a pair of antagonist premolars and molars that had at least one contact area during maximum intercuspal relationships, evaluated by asking the participants to clench on a 200 µm thick articulating paper, the presence of dental prostheses (fixed prosthesis and removable denture), the number of denture worn during meals (removable partial or complete denture, either maxillary or mandibular, or both, with number ranging from 0 to 2), the number of decayed, missing, filled teeth (DMFT index, based on 28 teeth), and the Russel's periodontal index which is presently preferred to the Community (namely CPITN) because it takes tooth mobility into account.

Intervention type: DIAGNOSTIC_TEST
Intervention: Food behavior
Description: Food selective behavior is assessed using a food selectivity questionnaire previously developed for French adults 34. Participants will be interviewed and asked to check each food item they do not eat among a list of 71 familiar products which includes raw foods and dishes from the following categories: starters, meat, fish, egg, garnish, dairy products, desserts, bread, and beverages. A food selectivity score corresponding to the total number of avoided foods will be assessed for each participant. For each avoided food, participants explain why they do not eat it among reasons including I don't know it, I dislike it, I suffer from chewing or swallowing it (oral discomfort), I experience difficulties digesting the food, This food is forbidden for medical reason, and This food is forbidden for ethical or religious reasons.

Intervention type: DIAGNOSTIC_TEST
Intervention: Food behavior
Description: Food selective behavior is assessed using a food selectivity questionnaire previously developed for French adults 34. Participants will be interviewed and asked to check each food item they do not eat among a list of 71 familiar products which includes raw foods and dishes from the following categories: starters, meat, fish, egg, garnish, dairy products, desserts, bread, and beverages. A food selectivity score corresponding to the total number of avoided foods will be assessed for each participant. For each avoided food, participants explain why they do not eat it among reasons including I don't know it, I dislike it, I suffer from chewing or swallowing it (oral discomfort), I experience difficulties digesting the food, This food is forbidden for medical reason, and This food is forbidden for ethical or religious reasons.
Study: NCT02518789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Dexmedetomidine
Description: Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose dexmedetomidine
Description: Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.~-Does not offer any other drugs within 5 min after completion of etomidate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate
Description: After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.~-Does not offer any other drugs within 5 min after completion of etomidate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etomidate
Description: After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.~-Does not offer any other drugs within 5 min after completion of etomidate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam，fentanyl，rocuronium
Description: Anesthesia induction：Intravenous injection midazolam 0.03 \~ 0.05 mg/kg, fentanyl 5 \~ 8 g/kg, rocuronium 0.6 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam，fentanyl，rocuronium
Description: Anesthesia induction：Intravenous injection midazolam 0.03 \~ 0.05 mg/kg, fentanyl 5 \~ 8 g/kg, rocuronium 0.6 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam，fentanyl，rocuronium
Description: Anesthesia induction：Intravenous injection midazolam 0.03 \~ 0.05 mg/kg, fentanyl 5 \~ 8 g/kg, rocuronium 0.6 mg/kg
Study: NCT01612013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC plus saline
Description: Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC plus sodium bicarbonate plus saline
Description: Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study: NCT01184872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin or Semi-Synthetic Penicillins (SSPs)
Description: Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days.
Study: NCT00774085

Intervention type: OTHER
Intervention: No intervention was given
Description: Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
Study: NCT02518789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol，remifentanil，cis atracurium
Description: Anesthesia maintenance：Intravenous infusion of propofol 4 \~ 6 mg/kg/h, remifentanil 0.1 \~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \~ 0.1mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol，remifentanil，cis atracurium
Description: Anesthesia maintenance：Intravenous infusion of propofol 4 \~ 6 mg/kg/h, remifentanil 0.1 \~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \~ 0.1mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol，remifentanil，cis atracurium
Description: Anesthesia maintenance：Intravenous infusion of propofol 4 \~ 6 mg/kg/h, remifentanil 0.1 \~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 \~ 0.1mg/kg
Study: NCT04201782

Intervention type: DRUG
Intervention: There are no disallowed treatments
Description: Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study: NCT00129636

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Additional specific letter written to patient
Study: NCT03934775

Intervention type: DEVICE
Intervention: Finapres Nova
Description: Non-invasive mesurement of hemodynamic parameters and heart rate variability
Study: NCT00453791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW805858
Description: GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
Study: NCT02111083

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: LY275585 administered SC.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: LY275585 administered SC.
Study: NCT03634423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet Spot: Flexible high incentive condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet Spot: Flexible low incentive condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study: NCT02505659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative re-education
Description: Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
Study: NCT00453791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW805858
Description: GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW805858
Description: GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW805858
Description: GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
Study: NCT04183374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Life style
Description: Lifestyle intervention i.e. diet, exercise, smoking cessation, alcohol limitations, dietary supplementation
Study: NCT03857919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TearCare
Description: The TearCare SmartLids will be applied to the external surface of each eyelid. The TearCare System will be turned on and heat will be delivered to the eyelids for 15 minutes. Immediately following the thermal portion of the procedure, the SmartLids will be removed and the doctor will manually express the meibomian glands.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow
Description: The LipiFlow activators will be placed between the inner eyelid and the corneal surface of each eye. The LipiFlow System will be turned on and heat and pressure will be delivered to each eyelid for 12 minutes.
Study: NCT04011657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compulsory CDSS
Description: Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
Study: NCT00613496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irbesartan
Description: Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
Study: NCT02385747

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hystroscopy
Description: Detailed hysteroscopic examination under general anesthesia Once the cavity entered, a panoramic view of the uterine cavity then systematic; first the fundus, then anterior, posterior and lateral walls of the uterus consecutively, ending by visualization of the uterine -tubal junctions, The thickness, colour, aspect and vasculature of the mucous membrane lining the uterine cavity was observed and recorded. If there is any intrauterine pathology detected; the shape, size and site were estimated.
Study: NCT00453791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW805858
Description: GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo MDI will be given to the subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo MDI will be given to the subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo MDI will be given to the subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo MDI will be given to the subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo MDI will be given to the subjects.
Study: NCT03512171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Description: One oral dose of dextroamphetamine (0.43mg/kg). The amphetamine is given in order to induce the release of their own dopamine for study with positron emission tomography (PET).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]Fallypride
Description: Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: [18F]Fallypride
Description: Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-FE-PE2I
Description: Radioligand for measuring dopamine transporters with positron emission tomography (PET)
Study: NCT01681160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: procedure:maggot therapy
Description: each times in maggot therapy continued for three days.wound assessment was done before and after any intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: patients receive ordinary treatment for diabetic foot
Study: NCT03634423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet Spot: Rigid high incentive condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweet Spot: Rigid low incentive condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOTW: High incentive control condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOTW: Low incentive control condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study: NCT03851718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture Procedure
Description: Each session will run about 30\~40 minutes at the Family Medicine Clinic and performed by a licensed acupuncturist. The expense of all three sessions will be reimbursed by the project, not billed to the participant. The following points CV17, ST18 (bilateral), ST36 (bilateral), SI1(bilateral) and LR3(bilateral) , adopted from TCM classic text and previous studies done in China, will be used for all three sessions .
Study: NCT03634423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOTW: High incentive treatment condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOTW: Low incentive treatment condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study: NCT03851718

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Power pumping
Description: It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days. During this one hour, the moms will be advised to pump for 20 minutes, rest for 10 minutes, pump for 10 minutes, then rest for 10 minutes and pump for 10 minutes. Alternatively they can also opt to pump and rest for every 10 minutes during the hour.
Study: NCT00453193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: 4 mg/m\^2 IV weekly for 4 weeks then every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 30 mg IV three times weekly
Study: NCT03634423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Think Twice: Control condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Think Twice: Treatment condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study: NCT00572039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PST
Description: PST will be delivered in subjects' homes over the course of 6 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: ST
Description: ST will be delivered in subjects' homes over the course of 6 weeks.
Study: NCT02894567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative test during a deep brain stimulation surgery
Description: The spiderSTN lead is inserted in a selected track in the brain, and is connected to external neuro-recorder/stimulator . Once the intraoperative test phase is completed, the test devices are removed and the DBS surgery resumes.
Study: NCT01170390

Intervention type: DRUG
Group type: OTHER
Intervention: All participants (Aviane)
Description: 20 mcg EE/0.1 mg LNG cyclically
Study: NCT03634423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WDR: Control condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study: NCT01170390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Portia
Description: 30 mcg EE/0.15 mg LNG cyclically
Study: NCT03634423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WDR: Treatment condition
Description: Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
Study: NCT00433836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.